Charles McWherter - 18 Aug 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Role: President of R&D
Signature: /s/ Paul Quinlan, as attorney-in-fact for Charles McWherter
Issuer symbol: N/A
Transactions as of: 18 Aug 2023
Net transactions value: -$140,629
Form type: 4
Filing time: 18 Aug 2023, 19:03:13 UTC
Previous filing: 19 Jul 2023
Next filing: 19 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CBAY	Common Stock	Options Exercise	$108,730	+21,746	+145%	$5.00	36,746	18 Aug 2023	Direct
transaction	CBAY	Common Stock	Sale	$249,359	-21,746	-59%	$11.47	15,000	18 Aug 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CBAY	Employee Stock Option (right to buy)	Options Exercise	$0	-10,404	-33%	$0.000000	20,805	18 Aug 2023	Common Stock	10,404	$5.00	Direct	F3
transaction	CBAY	Employee Stock Option (right to buy)	Options Exercise	$0	-708	-20%	$0.000000	2,828	18 Aug 2023	Common Stock	708	$5.00	Direct	F4
transaction	CBAY	Employee Stock Option (right to buy)	Options Exercise	$0	-236	-20%	$0.000000	942	18 Aug 2023	Common Stock	236	$5.00	Direct	F5
transaction	CBAY	Employee Stock Option (right to buy)	Options Exercise	$0	-3,892	-20%	$0.000000	15,566	18 Aug 2023	Common Stock	3,892	$5.00	Direct	F6
transaction	CBAY	Employee Stock Option (right to buy)	Options Exercise	$0	-6,506	-20%	$0.000000	26,022	18 Aug 2023	Common Stock	6,506	$5.00	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 24, 2023.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.285 to $11.63, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.
F4	The original option vested as to 1/4 of the underlying shares on July 23, 2008 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
F5	The original option vested as to 1/48 of the underlying shares monthly from October 15, 2009.
F6	The option vested in full on December 23, 2015.
F7	The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.